摘要
目的:探讨人血管紧张素Ⅱ1型受体(AT1R)基因多态性与高血压的关系,观察高血压发生、发展过程中各种危险因素对疾病的影响。方法:将我院2006年1月-2007年6月150例门诊及住院老年高血压患者设为观察组,另选取同期120例健康体检者设为对照组。所有患者均采用聚合酶链反应-单链构象多态性分析技术和酶解法检测外周血AT1R基因突变情况,收集患者5年随访的临床资料,均选用血管紧张素受体阻滞药(ARB)进行治疗,统计其严重不良事件的发生情况。结果:2组患者AT1R基因A1166C位点基因型频率和C等位基因频率比较差异均无统计学意义(P>0.05),严重不良事件的发生率主要与高血压导致心脏损伤后左室射血分数下降有关;按照正确的路径并综合考虑各种危险因素给予个体化治疗方案,可获得较好的预后;ARB治疗老年高血压安全、有效。结论:AT1R基因A1166C多态性与高血压的发生、发展尚未显示出相关性,C等位基因可能不是高血压的危险因子;对患者各种危险因素进行控制并制订个体化治疗方案,可对高血压的防治起到真正有益的作用,ARB对老年高血压治疗安全、有效。
OBJECTIVE： To explore the association between angiotensin Ⅱ type 1 receptor（AT1R） gene polymorphism and hy- pertension, and to observe the effects of various risk factors on disease in the process of occurrence and development of hyperten- sion. METHODS： 150 elderly outpatients and inpatients were randomly selected from our hospital during Jan. 2006--Jun. 2007 as observation group, and other 120 healthy volunteers were as control group. PCR-SSCP and enzymatic hydrolysis were adopted to test AT1R gene mutation of peripheral blood. Clinical information of selected cases was collected for 5 years. ARB was used for the treatment, and severe adverse events were analyzed statistically. RESULTS： The differences of Al166C site genotype frequency of AT1R gene and C allele frequency were not statistically different between 2 groups （P〉0.05）. The incidence of serious adverse events was related with the decrease of left ventricular ejection fraction （LVEF） after hypertension-induced heart damage; correct pathway and various risk factors were considered to provide individual treatment scheme so as to obtain sound prognosis; ARB treatment was proved to be safe and effective. CONCLUSION： The relationship of AT1R gene Al166C polymorphisms with the oc- currence and development of hypertension hasn＇ t been found, and C allele may not be risk factor to hypertension; multiple risk fac- tors control and treatment for individuals may play a genuinely beneficial role for the prevention and treatment of hypertension, and ARB is safe and effective for elderly hypertension patients.
出处
《中国药房》
CAS
CSCD
2012年第34期3247-3250,共4页
China Pharmacy
